AFFIRM (rate vs rhythm control) 2002

NCT00000556

1 Treatments

Studied treatment necessary rate control - beta-blockers, calcium-channel blockers, digoxin or combination of these drug.

Control treatment rhythm control - the antiarrhythmic drugs used included amiodarone, disopyramide, flecainide, moricizine, procainamide, propafenone, quinidine, sotalol, dofetilide or combinations chosen by the treating physician. Cardioversion could be employed if necessary.

Concomitant treatments -

Age (yr) 69.7 y

Female (%) 39.3 %

Rate-control targets achieved -

Resting heart-rate target achieved -

Exercise heart-rate target achieved -

2 Patients

Patients patients with recurrent atrial fibrillation and who were at least 65 years of age or who had other risk factors for stroke or death

Inclusion criteria -

Exclusion criteria -

heart failure 23.1%

Duration of permanent atrial fibrillation -

Duration of any atrial fibrillation -

CHADS2 score 3-6 -

CHADS2 score 2 -

CHADS2 score 0-1 -

Heart rate at rest -
Left ventricular ejection fraction

3 Methods

Blinding open

Design Parallel groups

Centers -

Geographical area -

Sizes 2027/2033

4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>death by cardiac arrhythmia</td>
<td>-/2027</td>
<td>-/2033</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>combined endpoint</td>
<td>388/2027</td>
<td>438/2033</td>
<td>0,89</td>
<td>[0,76; 1,04]</td>
</tr>
<tr>
<td>major bleedings</td>
<td>126/2027</td>
<td>113/2033</td>
<td>1,12</td>
<td>[0,86; 1,45]</td>
</tr>
<tr>
<td>CV death</td>
<td>-/2027</td>
<td>-/2033</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>Atrial fibrillation follow-up</td>
<td>-/2027</td>
<td>-/2033</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>hospitalisations (excluding those for cardioversion)</td>
<td>1220/2027</td>
<td>1374/2033</td>
<td>0,89</td>
<td>[0,78; 1,01]</td>
</tr>
<tr>
<td>death</td>
<td>310/2027</td>
<td>356/2033</td>
<td>0,87</td>
<td>[0,74; 1,03]</td>
</tr>
<tr>
<td>stroke/TIA</td>
<td>77/2027</td>
<td>80/2033</td>
<td>0,97</td>
<td>[0,70; 1,33]</td>
</tr>
<tr>
<td>Peripheral embolism</td>
<td>-/2027</td>
<td>-/2033</td>
<td>NA</td>
<td>-</td>
</tr>
</tbody>
</table>

5 References